Synapse - Early Drug Development Service

Search Within

Early Drug Development Service

Results (461)

A phase I, first-in-human dose study of the dual PI3K/mTOR inhibitor LY3023414 (LY) in patients (pts) with advanced cancer

Meeting Abstract

Moore, K. N.; Varghese, A. M.; Hyman, D. M.; Callies, S.; Lin, J.; Wacheck, V.; Pant, S.; Bauer, T. M.; Bendell, J. C.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

A phase II study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-0231D)

Meeting Abstract

Hyman, D. M.; Sill, M.; Cho, J. K.; Lankes, H. A.; Piekarz, R.; Hensley, M. L.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Identification of novel and potentially targetable receptor tyrosine kinase alterations in colorectal carcinoma using a 341 gene hybrid capture-based next-generation sequencing assay

Meeting Abstract

Hechtman, J. F.; Arcila, M. E.; Cheng, D. T.; Solit, D. B.; Yaeger, R. D.; Hyman, D. M.; Berger, M. F.; Shia, J.; Vakiani, E.; Zehir, A.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Phase I trial of the HSP-90 inhibitor PU-H71

Meeting Abstract

Gerecitano, J. F.; Modi, S.; Rampal, R.; Drilon, A. E.; Fury, M. G.; Gounder, M. M.; Harding, J. J.; Hyman, D. M.; Varghese, A. M.; Voss, M. H.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Physician toxicity attribution in phase I trials: Evaluating the effect of dose on the frequency of 11,909 toxicities

Meeting Abstract

Eaton, A.; Iasonos, A.; Gounder, M. M.; Pamer, E.; Drilon, A. E.; Vulih, D.; Smith, G. L.; Ivy, P.; Spriggs, D. R.; Hyman, D. M.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Dermatologic toxicities of 3,517 solid tumor patients on phase I clinical trials of the National Institutes of Health Cancer Therapy Evaluation Program (CTEP)

Meeting Abstract

Drilon, A. E.; Eaton, A.; Schindler, K.; Gounder, M. M.; Smith, G. L.; Vulih, D.; Harris, P. J.; Spriggs, D. R.; Ivy, P.; Iasonos, A.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Association of somatic mutations in DNA damage repair (DDR) genes with efficacy of platinum-based chemotherapy in advanced urothelial carcinoma

Meeting Abstract

Bambury, R. M.; Jordan, E.; Zabor, E. C.; Bouvier, N.; Al-Ahmadie, H.; Boyd, M. E.; Mullane, S. A.; Cha, E. K.; Ostrovnaya, I.; Hyman, D. M.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Comprehensive assessment of targetable alterations in lung adenocarcinoma samples with limited material using MSK-IMPACT, a clinical, hybrid capture-based, next-generation sequencing (NGS) assay

Meeting Abstract

Arcila, M. E.; Yu, H. A.; Drilon, A. E.; Riely, G. J.; Zehir, A.; Sadowska, J.; Hyman, D. M.; Kris, M. G.; Berger, M. F.; Ladanyi, M.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Genomic characterization of primary and metastatic prostate cancer (PC) using a targeted next-generation sequencing assay

Meeting Abstract

Abida, W.; Curtis, K. R.; Taylor, B. S.; Arcila, M. E.; Brennan, R.; Danila, D. C.; Rathkopf, D. E.; Morris, M. J.; Slovin, S. F.; Solit, D. B.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials

Journal Article

Hyman, D. M.; Eaton, A. A.; Gounder, M. M.; Pamer, E. G.; Pettiford, J.; Carvajal, R. D.; Percy Ivy, S.; Iasonos, A.; Spriggs, D. R.
Oncotarget (2015)

Fulltext@MSK | Save